$CODX
Co-Diagnostics, Inc. Stock $codx

$codx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224009955 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$467.9K	$3.555M	$6.812M
YoY Change	-22.28%	153.67%	-80.09%
Cost Of Revenue	$234.5K	$2.968M	$4.185M
YoY Change	-53.31%	475.42%	-23.65%
Gross Profit	$233.3K	$587.3K	$2.627M
YoY Change	134.01%	-33.69%	-90.86%
Gross Profit Margin	49.88%	16.52%	38.57%
Selling, General & Admin	$4.482M	$5.921M	$21.14M
YoY Change	-5.04%	-10.02%	-2.16%
% of Gross Profit	1920.94%	1008.1%	804.7%
Research & Development	$5.680M	$6.179M	$22.96M
YoY Change	13.28%	30.37%	31.68%
% of Gross Profit	2433.98%	1051.98%	874.07%
Depreciation & Amortization	$330.6K	$312.9K	$1.230M
YoY Change	4.61%	4.77%	-4.07%
% of Gross Profit	141.66%	53.27%	46.84%
Operating Expenses	$10.49M	$12.41M	$45.33M
YoY Change	4.4%	6.83%	-18.64%
Operating Profit	-$10.26M	-$11.83M	-$42.71M
YoY Change	3.1%	10.18%	58.29%
Interest Expense	$519.9K	$1.428M	$3.506M
YoY Change	-42.1%	456.03%	844.72%
% of Operating Profit
Other Income/Expense, Net	$970.1K		$4.596M
YoY Change	-49.88%		-43.49%
Pretax Income	-$9.289M	-$10.84M	-$38.11M
YoY Change	15.9%	-56.71%	102.21%
Income Tax	$22.76K	$3.834M	-$2.778M
% Of Pretax Income
Net Earnings	-$9.312M	-$14.68M	-$35.33M
YoY Change	61.8%	-33.0%	148.15%
Net Earnings / Revenue	-1990.37%	-412.82%	-518.68%
Basic Earnings Per Share	-$0.31		-$1.20
Diluted Earnings Per Share	-$0.31	-$0.50	-$1.20
COMMON SHARES
Basic Shares Outstanding	31.26M shares	30.58M shares	29.35M shares
Diluted Shares Outstanding	29.84M shares		29.35M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.96M	$58.55M	$58.55M
YoY Change	-33.63%	-27.95%	-27.95%
Cash & Equivalents	$23.10M	$14.92M
Short-Term Investments	$26.86M	$43.63M	$43.63M
Other Short-Term Assets	$1.750M	$1.597M	$1.597M
YoY Change	91.69%	109.82%	109.82%
Inventory	$1.550M	$1.665M	$1.665M
Prepaid Expenses
Receivables	$434.9K	$303.9K	$303.9K
Other Receivables	$0.00	$26.95K	$26.95K
Total Short-Term Assets	$53.70M	$62.14M	$62.14M
YoY Change	-37.5%	-32.99%	-32.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.183M	$3.036M	$6.003M
YoY Change	26.81%	19.54%	106.16%
Goodwill
YoY Change
Intangibles	$26.33M	$26.40M
YoY Change	-1.25%	-1.36%
Long-Term Investments	$702.4K	$773.4K	$773.4K
YoY Change	-26.06%	14.97%	14.97%
Other Assets
YoY Change
Total Long-Term Assets	$32.97M	$33.18M	$33.18M
YoY Change	6.11%	9.31%	9.31%
TOTAL ASSETS
Total Short-Term Assets	$53.70M	$62.14M	$62.14M
Total Long-Term Assets	$32.97M	$33.18M	$33.18M
Total Assets	$86.67M	$95.32M	$95.32M
YoY Change	-25.92%	-22.56%	-22.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.028M	$1.482M	$1.482M
YoY Change	144.34%	55.64%	55.63%
Accrued Expenses	$1.325M	$2.173M	$3.011M
YoY Change	-11.24%	132.54%	144.5%
Deferred Revenue	$306.5K	$362.4K
YoY Change	1591.37%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.270M	$5.748M	$5.748M
YoY Change	45.97%	48.38%	48.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.049M	$3.559M	$3.559M
YoY Change	19.39%	56.47%	56.47%
Total Long-Term Liabilities	$3.049M	$3.559M	$3.559M
YoY Change	10.58%	-24.15%	56.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.270M	$5.748M	$5.748M
Total Long-Term Liabilities	$3.049M	$3.559M	$3.559M
Total Liabilities	$8.318M	$9.307M	$9.307M
YoY Change	30.65%	8.65%	8.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.714M	$4.598M
YoY Change	-113.79%	-88.48%
Common Stock	$36.13K	$36.11K
YoY Change	3.74%	3.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$15.58M	$15.58M
YoY Change	6.0%	9.6%
Treasury Stock Shares
Shareholders Equity	$78.35M	$86.01M	$86.01M
YoY Change
Total Liabilities & Shareholders Equity	$86.67M	$95.32M	$95.32M
YoY Change	-25.92%	-22.56%	-22.56%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$9.312M	-$14.68M	-$35.33M
YoY Change	61.8%	-33.0%	148.15%
Depreciation, Depletion And Amortization	$330.6K	$312.9K	$1.230M
YoY Change	4.61%	4.77%	-4.07%
Cash From Operating Activities	-$8.490M	-$4.779M	-$22.08M
YoY Change	54.39%	19.17%	-436.17%
INVESTING ACTIVITIES
Capital Expenditures	$402.3K	$464.6K	$1.365M
YoY Change	123.57%	58.41%	-4.36%
Acquisitions
YoY Change
Other Investing Activities	$17.08M	$10.08M	$16.75M
YoY Change	-263.35%	-119.01%	-129.53%
Cash From Investing Activities	$16.67M	$9.615M	$15.39M
YoY Change	-256.8%	-118.04%	-126.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.364M
YoY Change			-90.28%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-159.7K	-$1.364M
YoY Change		-86.89%	-90.28%
NET CHANGE
Cash From Operating Activities	-$8.490M	-4.779M	-$22.08M
Cash From Investing Activities	$16.67M	9.615M	$15.39M
Cash From Financing Activities		-159.7K	-$1.364M
Net Change In Cash	$8.182M	4.677M	-$8.057M
YoY Change	-149.25%	-107.99%	-87.72%
FREE CASH FLOW
Cash From Operating Activities	-$8.490M	-$4.779M	-$22.08M
Capital Expenditures	$402.3K	$464.6K	$1.365M
Free Cash Flow	-$8.893M	-$5.243M	-$23.45M
YoY Change	56.58%	21.85%	-556.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001692415
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent		usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments		usd
CY2023	CODX	Stock Issued During Period Value Acquisitions Adjustments StockIssuedDuringPeriodValueAcquisitionsAdjustments		usd
CY2023	CODX	Fair Value Of Contingent Common Stock And Warrants Issued As Consideration For Business Acquisitions FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions		usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
CY2023	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
CY2022	CODX	Change In Valuation Allowance ChangeInValuationAllowance		usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch		usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38148
CY2023	dei	Entity Registrant Name EntityRegistrantName	CO-DIAGNOSTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	UT
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2609396
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 S. Foothill Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84109
CY2023	dei	City Area Code CityAreaCode	(801)
CY2023	dei	Local Phone Number LocalPhoneNumber	438-1036
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	CODX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	33000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31259668	shares
CY2023	dei	Auditor Firm AuditorFirmId	270
CY2022	dei	Auditor Firm AuditorFirmId	457
CY2023	dei	Auditor Name AuditorName	Tanner LLC
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2022	dei	Auditor Name AuditorName	Haynie & Company
CY2022	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14916878	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	43631510	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	58289066	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	303926	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1664725	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	26955	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1870419	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1597114	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	761187	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	62141108	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	92733671	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3035729	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2539483	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2966774	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	372115	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26403667	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2023Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	773382	usd
CY2022Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	672679	usd
CY2023Q4	us-gaap	Assets Assets	95320660	usd
CY2022Q4	us-gaap	Assets Assets	123086281	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1482109	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	952296	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2172959	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	934447	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	838387	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297209	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	891666	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1689471	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	362449	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5747570	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3873423	usd
CY2023Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	659186	usd
CY2022Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1181284	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2417987	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2152180	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50708	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	748109	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	1042885	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3559475	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4692864	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9307045	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8566287	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36108346	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31259668	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34754265	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30872607	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	36108	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	34754	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4848678	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3881658	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	15575795	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	14211866	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	96808436	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88472935	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	146700	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	293140	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4598166	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	39931031	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	86013615	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519994	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95320660	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123086281	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6812038	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34218209	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	4184949	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5481093	usd
CY2023	us-gaap	Gross Profit GrossProfit	2627089	usd
CY2022	us-gaap	Gross Profit GrossProfit	28737116	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6860815	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7344628	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14279441	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14262963	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22962593	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17438098	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1230474	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1282718	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15388546	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	45333323	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	55716953	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-42706234	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-26979837	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	1161913	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	704045	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	2243059	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2578	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
CY2023	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	1092581	usd
CY2022	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7899644	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	100703	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-332969	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4595678	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8132603	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38110556	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18847234	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2777691	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4608985	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35332865	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-146440	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	293140	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-146440	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	293140	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35479305	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13945109	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29346599	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31479028	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29346599	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31479028	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475099	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77870	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	7543223	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	480776	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	14211866	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	293140	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	177870	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519994	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519994	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	8336855	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1363929	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-146440	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35332865	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	86013615	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	86013615	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35332865	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1230474	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1282718	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15388546	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	8336855	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7543223	usd
CY2023	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	1092581	usd
CY2022	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7899644	usd
CY2023	CODX	Noncash Lease Expense NoncashLeaseExpense	47992	usd
CY2022	CODX	Noncash Lease Expense NoncashLeaseExpense	30430	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	2243059	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	100703	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-332969	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2578	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2417987	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4810457	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	612809	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2461032	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	3233281	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	148099	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2536988	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14924427	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1082536	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	224094	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-413140	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3673309	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	362449	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-150000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-522098	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2201250	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1768326	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2483821	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22081865	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6568737	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1365306	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1427512	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	127251619	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11255266	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	110497444	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	67995926	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15388869	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58168172	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1363929	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	14211866	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1363929	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14033996	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8056925	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-65633431	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22973803	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88607234	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14916878	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22973803	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	55975	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4498742	usd
CY2023	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	673	usd
CY2022	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	218906	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3203146	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	681327	usd
CY2022	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments	1593	usd
CY2022	CODX	Stock Issued During Period Value Acquisitions Adjustments StockIssuedDuringPeriodValueAcquisitionsAdjustments	480776	usd
CY2022	CODX	Fair Value Of Contingent Common Stock And Warrants Issued As Consideration For Business Acquisitions FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions	199359	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zgfVcYfuqaVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zZMBHjoqHgu1">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	504264	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	200338	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	303926	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6552249	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3098526	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1664725	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	700467	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	964258	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1327264	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3983209	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2760011	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	15388546	usd
CY2023	CODX	Grant Funding Revenue GrantFundingRevenue	5800000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	300000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22962593	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17438098	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z3uady2vZ1H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zpxT2VGITII6">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company had certain customers which were each responsible for generating <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeWhSgluJF3a" title="Concentration risk percentage"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zjPJNOTSiCGi" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the years ended December 31, 2023 and 2022, respectively. Two customers accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvaMjr3yRLV9" title="Concentration risk percentage">28</span>% of product revenue for the year ended December 31, 2023 and one customer accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxx0kXFeHxH7" title="Concentration risk percentage">37</span>% of product revenue for the year ended December 31, 2022. One granting agency accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneGrantingAgencyMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0UiTEgdSQP8" title="Concentration risk percentage">100</span>% of grant revenue for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Three customers accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5HhCKDJFR9h" title="Concentration risk percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zB4AiwtztUO5" title="Concentration risk percentage">10</span></span>% of accounts receivable at December 31, 2023 and 2022, respectively. These customers together accounted for approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zcVLqDdo9Oll" title="Concentration risk percentage">97</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zkFZiWlLg7dj" title="Concentration risk percentage">61</span>% of accounts receivable at December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	58401688	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	146700	usd
CY2023Q4	us-gaap	Trading Securities TradingSecurities	58548388	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14916878	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	43631510	usd
CY2022Q4	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	80873628	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	389241	usd
CY2022Q4	us-gaap	Trading Securities TradingSecurities	81262869	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	58289066	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2232495	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1372248	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3035729	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2539483	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14706818	usd
CY2022	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	681728	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15388546	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-791333	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26403667	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-426667	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	302667	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	302667	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1643186	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	428354	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	9958	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	159725	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	519815	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	346368	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2172959	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	934447	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6812038	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34218209	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6812038	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34218209	usd
CY2023	CODX	Increase Due To Prepayments From Customers IncreaseDueToPrepaymentsFromCustomers	32570	usd
CY2023	CODX	Increase Due To Prepayments From Grants Received IncreaseDueToPrepaymentsFromGrantsReceived	329879	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	362449	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35332865	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29346599	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31479028	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29346599	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31479028	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1111363	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.12
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.31
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	70791	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.10
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised	0.51
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
CY2023	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y10M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1040572	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.19
CY2023Q4	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable	1.37
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y10M20D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	526281	shares
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	8.15
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	4.01
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P4Y8M12D
CY2022	CODX	Share Based Compensation Issued For Adjustments To Contingent Purchase Consideration ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration	8719	shares
CY2022	CODX	Issued For Adjustments To Contingent Purchase Consideration Period Weighted Average Exercise Price IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice	9.13
CY2022	CODX	Issued For Adjustments To Contingent Purchase Consideration Weighted Average Grant Date Fair Value IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue	1.88
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	50000	shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	2.00
CY2022	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.22
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2022Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	8.81
CY2022Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	2.43
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3	P4Y
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.035	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2023Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Options Non Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice	8.81
CY2023Q4	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	1.29
CY2023	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3	P3Y
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	465000	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8336855	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7543223	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	84435	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	563821	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-540240	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-266248	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-455805	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	297573	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7228611	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3945090	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2068509	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-961468	usd
CY2023	CODX	Change In Valuation Allowance ChangeInValuationAllowance	-6975234	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-2321886	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-4906558	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2777691	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4608985	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.014	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.036	pure
CY2023	CODX	Effective Income Tax Rate Reconciliation Contingent Consideration Remeasurement EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement	0.006	pure
CY2022	CODX	Effective Income Tax Rate Reconciliation Contingent Consideration Remeasurement EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement	0.088	pure
CY2023	CODX	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	0.000	pure
CY2022	CODX	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	-0.171	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.006	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.046	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.111	pure
CY2023	CODX	Effective Income Tax Rate Reconciliation Change In Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance	-0.012	pure
CY2022	CODX	Effective Income Tax Rate Reconciliation Change In Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance	0.021	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.183	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.073	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.245	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	58158	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	98141	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	734631	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	765004	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	620551	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	566076	usd
CY2023Q4	CODX	Deferred Tax Assets Costs DeferredTaxAssetsCosts	7337629	usd
CY2022Q4	CODX	Deferred Tax Assets Costs DeferredTaxAssetsCosts	3460159	usd
CY2023Q4	CODX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	742131	usd
CY2022Q4	CODX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	85899	usd
CY2023Q4	CODX	Deferred Tax Assets Uniform Capitalization DeferredTaxAssetsUniformCapitalization	43943	usd
CY2022Q4	CODX	Deferred Tax Assets Uniform Capitalization DeferredTaxAssetsUniformCapitalization	168936	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4040601	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1688255	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15265899	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5144215	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6938829	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8327070	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5144215	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	672416	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	609261	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6552255	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6608914	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	329768	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	156053	usd
CY2023Q4	CODX	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	736226	usd
CY2022Q4	CODX	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	91873	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	36405	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	96101	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8327070	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7562202	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2417987	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	16300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	16900000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	800000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1078431	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1469577	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1469577	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1067853	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	273569	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1045590	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	66127	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	34035	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	730842	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	677901	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1078431	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1469577	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	100162	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	34035	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	813743	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	198261	usd
CY2023	us-gaap	Lease Cost LeaseCost	1012004	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	996676	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1018383	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	714630	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	300591	usd
CY2023Q4	CODX	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	308462	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3338742	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	348175	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2990567	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	838387	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2152180	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	954013	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062	pure
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	30000000.0	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3881658	shares
CY2023	CODX	Repurchases Of Common Stock RepurchasesOfCommonStock	967020	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4848678	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-009955-index-headers.html	Edgar Link	pending
0001493152-24-009955-index.html	Edgar Link	pending
0001493152-24-009955.txt	Edgar Link	pending
0001493152-24-009955-xbrl.zip	Edgar Link	pending
codx-20231231.xsd	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
codx-20231231_lab.xml	Edgar Link	unprocessable
codx-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
codx-20231231_cal.xml	Edgar Link	unprocessable
codx-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CODX
Co-Diagnostics, Inc. Stock $codx

2024 Q1 Form 10-K Financial Statement

#000149315224009955 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX Co-Diagnostics, Inc. Stock $codx

2024 Q1 Form 10-K Financial Statement

#000149315224009955 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX
Co-Diagnostics, Inc. Stock $codx